Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Tardive dyskinesia (TD) is a late-onset adverse effect of dopamine receptor-blocking medications, characterized by involuntary movements primarily affecting the mouth, though other body parts may be involved. Severity of TD varies from mild to debilitating and is usually irreversible. Despite the existence of treatments such as VMAT2 inhibitors, TD remains underdiagnosed, with 40,000 patients treated of an estimated 2.6 million affected US individuals. This study demonstrates a novel, efficient, and reliable method to detect and bring TD to psychiatrists' attention using video-based artificial intelligence. Individuals taking antipsychotic medications were enrolled in Study 1 (n = 46) between March and November 2018, in Study 2 (n = 136) between May 2023 and May 2024, and in Study 3 (n = 174) between July 2023 and May 2024. Participants completed video assessments. A vision transformer machine-learning architecture was evaluated by calculating the area under the receiver operating characteristic curve (AUC), sensitivity, and specificity compared with a reference standard of the trained raters' evaluation of TD on the Abnormal Involuntary Movement Scale. The algorithm reached an AUC of 0.89 in the combined validation cohort across Studies 1, 2, and 3. The model demonstrated strong and reliable levels of agreement, outperforming human raters. Our algorithm reliably detected suspected TD, reaching higher sensitivity and specificity than trained raters using the standard assessment. The algorithm can be used to monitor patients taking antipsychotic medications, allowing scarce resources to assess identified patients for a conclusive diagnosis by psychiatrists.

Download full-text PDF

Source
http://dx.doi.org/10.4088/JCP.25m15792DOI Listing

Publication Analysis

Top Keywords

tardive dyskinesia
8
video-based artificial
8
artificial intelligence
8
antipsychotic medications
8
2023 2024
8
sensitivity specificity
8
detecting tardive
4
dyskinesia video-based
4
intelligence tardive
4
dyskinesia late-onset
4

Similar Publications

Introduction: Tardive dyskinesia (TD), a persistent and often debilitating movement disorder, is associated with prolonged exposure to dopamine receptor-blocking agents. Individuals aged ≥ 60 years are at increased risk for TD and TD-related burden (e.g.

View Article and Find Full Text PDF

The Effects of Antipsychotic Dose Reduction on Movement Disorders and Cardiometabolic Indices in Patients Remitted from a First Episode of Psychosis.

Schizophr Bull

August 2025

Department of Biomedical Sciences, Cognitive Neuroscience Center, University Medical Center Groningen (UMCG), University of Groningen, Groningen 9713 GZ, The Netherlands.

Background And Hypothesis: The extent to which tapering antipsychotic (AP) attenuates AP-related movement disorders and cardiometabolic dysfunction remains unclear. We aim to investigate the long-term effects of AP-dose reduction on these adverse effects in patients remitted from a first episode of psychosis (FEP).

Study Methods: We included 293 FEP participants from the HAMLETT trial.

View Article and Find Full Text PDF

Melanostatin (MIF-1) is a naturally occurring neuropeptide acting as a positive allosteric modulator (PAM) of dopamine D receptors (DR), underscoring its potential for therapeutic use in central nervous system disorders associated with dopaminergic dysregulation, including depression, drug addiction, restless legs syndrome, tardive dyskinesia, and Parkinson's disease. In this work, a new series of MIF-1 analogs using l-pipecolic acid as an l-proline surrogate was synthesized and pharmacologically evaluated by functional assays at the DR. In this series, methyl l-pipecolyl-l-leucylglycinate () was found to exhibit superior performance compared to MIF-1 by promoting a 4.

View Article and Find Full Text PDF

Introduction: Adverse drug reactions may be increased by combining benzodiazepines and drugs related (BZDR) with clozapine. We aimed to synthesize clinically relevant information on the risks and benefits co-prescribing clozapine and BZDR.

Methods: A systematic review was performed on articles identified with MEDLINE, Web of Sciences and PsycINFO search from inception through August 2024 using the algorithm 'clozapine' AND 'benzodiazepines'.

View Article and Find Full Text PDF

Valbenazine improved chorea in individuals with Huntington's disease compared to placebo in a phase 3, placebo-controlled study (KINECT-HD). Population pharmacokinetics (PK) and exposure-response (E-R) analyses focused on understanding the PK characteristics of valbenazine and its active metabolite, [+]-α-dihydrotetrabenazine ([+]-α-HTBZ), and their correlation with clinical efficacy measured by the total maximal chorea (TMC) score. Consistent with previous analyses, a two-compartmental population PK model adequately described valbenazine and [+]-α-HTBZ plasma disposition, generating reliable individual-predicted exposure levels for sequential E-R analysis.

View Article and Find Full Text PDF